People: Ventrus Biosciences Inc (VTUS.W)

VTUS.W on CBOE When Trading NASDAQ Global Select Market

2.62USD
21 May 2013
Price Change (% chg)

$-0.02 (-0.76%)
Prev Close
$2.64
Open
$2.63
Day's High
$2.63
Day's Low
$2.62
Volume
300
Avg. Vol
192
52-wk High
$12.41
52-wk Low
$2.02

Search Stocks

Summary

Name Age Since Current Position

Russell Ellison

 64 2011 Chairman of the Board, Chief Executive Officer, Chief Medical Officer

David Barrett

 37 2010 Chief Financial Officer

Anthony Altig

 56 2012 Independent Director

Mark Auerbach

 2010 Independent Director

Joseph Felder

 51 2008 Independent Director

Myron Holubiak

 66 2010 Independent Director
» Insider Trading

Biographies

Name Description

Russell Ellison

 Dr. Russell H. Ellison, M.D., M.Sc., is Chairman of the Board, Chief Executive Officer, Chief Medical Officer of Ventrus Biosciences Inc. Dr. Ellison joined the company as a director, Chief Executive Officer and Chief Medical Officer in June 2010. He was elected Chairman of the company's Board in January 2011. From July 2007 to January 2010, Dr. Ellison served as Executive Vice President of Paramount Biosciences LLC, a global pharmaceutical development and healthcare investment firm. From October 2005 until June 2007, Dr. Ellison served as the Vice President of Clinical Development of Fibrogen, Inc., a privately held biotechnology company. From August 2002 to December 2004, Dr. Ellison served as Vice President of Medical Affairs and Chief Medical Officer of Sanofi-Synthelabo, USA, a pharmaceutical company. From May 1997 to August 2002, Dr. Ellison served as Vice President, Medical Affairs and Chief Medical Officer of Hoffman-La Roche, Inc., a pharmaceutical company. From July 2007 until December 2010, Dr. Ellison served as a director of CorMedix, Inc., a pharmaceutical company that went public in March 2010. He currently serves as a director of several privately held development stage biotechnology companies. Dr. Ellison holds an M.D. from the University of British Columbia and an M.Sc. (with distinction) from The London School of Tropical Medicine and Hygiene.

David Barrett

 Mr. David J. Barrett is Chief Financial Officer of Ventrus Biosciences Inc., since July 2010. From April 2006 to September 2009, Mr. Barrett served as Chief Financial Officer of Neuro-Hitech, Inc., a public company focused on developing, marketing and distributing branded and generic pharmaceutical products. From September 2003 to April 2006, Mr. Barrett was the Chief Financial Officer /Vice President of Finance of Overture Asset Managers and Overture Financial Services, which, at the time, was a start-up asset management firm that assembled investment products and platforms to distribute turnkey and unbundled investment solutions to financial intermediaries and institutional investors. From July 1999 to September 2003, Mr. Barrett was employed as a Manager at Deloitte & Touche, LLP. Mr. Barrett received his B.S. in Accounting and Economics in May of 1998 and his M.S. in Accounting in May of 1999 from the University of Florida. He is a certified public accountant.

Anthony Altig

 Mr. Anthony E. Altig is Independent Director of Ventrus Biosciences, Inc., effective January 17, 2012. Mr. Altig is the Chief Financial Officer of Biotix Holdings, Inc., a company that manufactures microbiological consumables. From December 2004 to June 2007, Mr. Altig served as the Chief Financial Officer of Diversa Corporation (subsequently Verenium Corporation), a public company developing specialized industrial enzymes. Prior to joining Diversa, Mr. Altig served as the Chief Financial Officer of Maxim Pharmaceuticals, Inc., a public biopharmaceutical company, from 2002 to 2004. In addition, Mr. Altig serves as a director and chair of the Audit Committee for MultiCell Technologies, Inc., a biopharmaceutical company, and a director for TearLab Corporation (formerly OccuLogix, Inc.), an eyecare technology company, and Optimer Pharmaceuticals, Inc., a pharmaceutical company, all of which are public companies.

Mark Auerbach

 Mr. Mark Auerbach, CPA, is Independent Director of Ventrus Biosciences Inc., since November 2010. Over the last 17 years, Mr. Auerbach has served as a director for several companies. Mr. Auerbach currently is a director and chairman of the audit committee of Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR), a public company. He has held those positions since June 2005. From January 2006 through March 2010, Mr. Auerbach served as the chairman of the board of directors for Neuro-Hitech, Inc., an early-stage pharmaceutical company specializing in brain degenerative diseases. From June 2007 through August 2009, he served as a director for Collexis Holdings, Inc., a company which develops knowledge management and discovery software. From July 2007 through February 2009, Mr. Auerbach also served as a director for RxElite Holdings, Inc., a company which develops, manufactures, and markets generic prescription drug products in specialty generic markets. From September 2003 through October 2006, Mr. Auerbach served as executive chairman of the board of directors for Par Pharmaceutical Companies, Inc., a manufacturer and marketer of generic pharmaceuticals and the parent of Par Pharmaceutical, Inc., and served as chair of the audit committee prior to becoming executive chairman. From 1993 to 2005, Mr. Auerbach served as chief financial officer of Central Lewmar LLC, a national paper distributor. Mr. Auerbach received his B.S. degree in accounting from Rider University.

Joseph Felder

 Dr. Joseph Felder, M.D., is Independent Director of Ventrus Biosciences Inc. Dr. Felder joined Board in May 2008. Dr. Felder has been a gastroenterologist since 1992 after having completed his post-doctoral training and fellowship at Lenox Hill Hospital in New York City. He is currently in private practice in Manhattan. He received his B.S. from the City University of New York and his M.D. from the University of Texas at San Antonio in 1987. He practices out of Lenox Hill Hospital, a teaching affiliate of the New York University School of Medicine, where he is an adjunct and attending physician in the departments of Medicine and Gastroenterology. His responsibilities there include teaching obligations. He has done clinical research in gastroenterology, specifically in the subject of inflammatory bowel disease and is published in this field in various international journals as well as textbooks. He is a co-chairman of the medical advisory board of the Crohn’s and Colitis Foundation of America in New York.

Myron Holubiak

 Mr. Myron Z. Holubiak is Independent Director of Ventrus Biosciences Inc. Mr. Holubiak joined Board in July 2010. Mr. Holubiak currently serves as President of 1-800-DOCTORS, Inc., a position he has held since May 2007. Mr. Holubiak is the former President of Roche Laboratories, Inc., USA, a research-based pharmaceutical company, a position he held from December 1998 to August 2001. He held many sales and marketing positions at Roche Laboratories in his 19-year tenure. Mr. Holubiak was a director and the President and Chief Operating Officer of HealthSTAR Communications, Inc., the private health care marketing communications company in the U.S. from November 2003 to April 2007, and he served as HealthSTAR Group’s President, Field Level Marketing Group from August 2002 to October 2003. Mr. Holubiak served on the board of trustees of the Robert Wood Johnson Hospital Foundation in 2000 and 2001. Since September 2002 he has served on the board of directors of BioScrip, Inc., a specialty pharmacy company. Mr. Holubiak previously served on the board of directors of Nastech, Inc., a biotechnology-based pharmaceutical company now called Marina Biotech, Inc. Mr. Holubiak received his B.S. in Molecular Biology and Biophysics from the University of Pittsburgh.

Basic Compensation

Name Fiscal Year Total

Russell Ellison

 808,750

David Barrett

 560,000

Anthony Altig

 --

Mark Auerbach

 --

Joseph Felder

 --

Myron Holubiak

 --
As Of 30 Dec 2011

Options Compensation

Name Options Value

Russell Ellison

 0 0

David Barrett

 0 0

Anthony Altig

 0 0

Mark Auerbach

 0 0

Joseph Felder

 0 0

Myron Holubiak

 0 0

Insider Trading

Name Shares Traded Price

ALTIG ANTHONY E

 15,000 $3.00

ELLISON RUSSELL H

 5,624 $2.59

ELLISON RUSSELL H

 9,376 $2.52
» Full list on Insider Trading
Search Stocks